Outcome of pulmonary multidrug-resistant tuberculosis

A 6-yr follow-up study

C. Y. Chiang, D. A. Enarson, M. C. Yu, K. J. Bai, R. M. Huang, C. J. Hsu, J. Suo, T. P. Lin

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (Cl) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% Cl 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.

Original languageEnglish
Pages (from-to)980-985
Number of pages6
JournalEuropean Respiratory Journal
Volume28
Issue number5
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Pulmonary Tuberculosis
Ofloxacin
Pharmaceutical Preparations
Recurrence
Fluoroquinolones
Taiwan
Therapeutics
Referral and Consultation
Retrospective Studies
Confidence Intervals

Keywords

  • Death
  • Follow-up
  • Multidrug resistant
  • Relapse
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Outcome of pulmonary multidrug-resistant tuberculosis : A 6-yr follow-up study. / Chiang, C. Y.; Enarson, D. A.; Yu, M. C.; Bai, K. J.; Huang, R. M.; Hsu, C. J.; Suo, J.; Lin, T. P.

In: European Respiratory Journal, Vol. 28, No. 5, 11.2006, p. 980-985.

Research output: Contribution to journalArticle

Chiang, C. Y. ; Enarson, D. A. ; Yu, M. C. ; Bai, K. J. ; Huang, R. M. ; Hsu, C. J. ; Suo, J. ; Lin, T. P. / Outcome of pulmonary multidrug-resistant tuberculosis : A 6-yr follow-up study. In: European Respiratory Journal. 2006 ; Vol. 28, No. 5. pp. 980-985.
@article{ebf0f5b92ab64e73aadbb54552d16faf,
title = "Outcome of pulmonary multidrug-resistant tuberculosis: A 6-yr follow-up study",
abstract = "A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9{\%}) males and 84 (28.1{\%}) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2{\%}) were cured, 31 (10.4{\%}) failed, 28 (9.4{\%}) died and 87 (29.1{\%}) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2{\%}) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95{\%} confidence interval (Cl) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95{\%} Cl 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.",
keywords = "Death, Follow-up, Multidrug resistant, Relapse, Tuberculosis",
author = "Chiang, {C. Y.} and Enarson, {D. A.} and Yu, {M. C.} and Bai, {K. J.} and Huang, {R. M.} and Hsu, {C. J.} and J. Suo and Lin, {T. P.}",
year = "2006",
month = "11",
doi = "10.1183/09031936.06.00125705",
language = "English",
volume = "28",
pages = "980--985",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Outcome of pulmonary multidrug-resistant tuberculosis

T2 - A 6-yr follow-up study

AU - Chiang, C. Y.

AU - Enarson, D. A.

AU - Yu, M. C.

AU - Bai, K. J.

AU - Huang, R. M.

AU - Hsu, C. J.

AU - Suo, J.

AU - Lin, T. P.

PY - 2006/11

Y1 - 2006/11

N2 - A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (Cl) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% Cl 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.

AB - A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (Cl) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% Cl 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.

KW - Death

KW - Follow-up

KW - Multidrug resistant

KW - Relapse

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=33847382372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847382372&partnerID=8YFLogxK

U2 - 10.1183/09031936.06.00125705

DO - 10.1183/09031936.06.00125705

M3 - Article

VL - 28

SP - 980

EP - 985

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 5

ER -